Please assess the completion status of the following clinical trial:

Trial Title: Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult SCD patients with genotypes SS, SC, SB+, or SB-~Exclusion Criteria:~* Patients with sickle cell trait~* Allergic to both morphine sulfate and hydromorphone,~* Patients who have an explicit care plan that states they cannot be admitted to the hospital for pain control,~* Non-English speaking,~* Patients admitted for a medical complication,~* Record of \>24 ED visits in the prior 12 months,~* Children

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient Specific dose of Morphine Sulfate or Hydromorphone (Type: EXPERIMENTAL): A patient-specific analgesic protocol for use in the ED to manage VOC crises. Following randomization, a patient's healthcare team will develop a specific analgesic protocol for use during future ED visits for VOC occurring during the study period (up to 5 visits). Treatment protocols will include either morphine sulfate or hydromorphone (delivered intravenous or sub-cutaneous). Dosage and frequency will be based on a patient's prior treatment history.
- Standard dose of Morphine Sulfate or Hydromorphone (Type: ACTIVE_COMPARATOR): A standardized analgesic protocol (based on recent NHLBI recommendations) for use in the ED to manage VOC crises. Treatment protocol will include either morphine sulfate or hydromorphone (delivered intravenous or sub-cutaneous), with dosage based on weight. Repeat doses of opioids may be administered every 20-30 minutes as needed, although dosage will be maintained or provided at no more than 25% above the initial dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).